Ferraro Daniel J, Funk Ryan K, Blackett John William, Ju Michelle R, DeWees Todd A, Chicoine Michael R, Dowling Joshua L, Rich Keith M, Drzymala Robert E, Zoberi Imran, Simpson Joseph R, Jaboin Jerry J
Department of Radiation Oncology, Washington University in Saint Louis, 4511 Forest Park Avenue/Campus Box 8224, St, Louis, MO, USA.
Radiat Oncol. 2014 Jan 27;9:38. doi: 10.1186/1748-717X-9-38.
While most meningiomas are benign, aggressive meningiomas are associated with high levels of recurrence and mortality. A single institution's Gamma Knife radiosurgical experience with atypical and malignant meningiomas is presented, stratified by the most recent WHO classification.
Thirty-one patients with atypical and 4 patients with malignant meningiomas treated with Gamma Knife radiosurgery between July 2000 and July 2011 were retrospectively reviewed. All patients underwent prior surgical resection. Overall survival was the primary endpoint and rate of disease recurrence in the brain was a secondary endpoint. Patients who had previous radiotherapy or prior surgical resection were included. Kaplan-Meier and Cox proportional hazards models were used to estimate survival and identify factors predictive of recurrence and survival.
Post-Gamma Knife recurrence was identified in 11 patients (31.4%) with a median overall survival of 36 months and progression-free survival of 25.8 months. Nine patients (25.7%) had died. Three-year overall survival (OS) and progression-free survival (PFS) rates were 78.0% and 65.0%, respectively. WHO grade II 3-year OS and PFS were 83.4% and 70.1%, while WHO grade III 3-year OS and PFS were 33.3% and 0%. Recurrence rate was significantly higher in patients with a prior history of benign meningioma, nuclear atypia, high mitotic rate, spontaneous necrosis, and WHO grade III diagnosis on univariate analysis; only WHO grade III diagnosis was significant on multivariate analysis. Overall survival was adversely affected in patients with WHO grade III diagnosis, prior history of benign meningioma, prior fractionated radiotherapy, larger tumor volume, and higher isocenter number on univariate analysis; WHO grade III diagnosis and larger treated tumor volume were significant on multivariate analysis.
Atypical and anaplastic meningiomas remain difficult tumors to treat. WHO grade III diagnosis and treated tumor volume were significantly predictive of recurrence and survival on multivariate analysis in aggressive meningioma patients treated with radiosurgery. Larger tumor size predicts poor survival, while nuclear atypia, necrosis, and increased mitotic rate are risk factors for recurrence. Clinical and pathologic predictors may help identify patients that are at higher risk for recurrence.
虽然大多数脑膜瘤是良性的,但侵袭性脑膜瘤与高复发率和死亡率相关。本文介绍了一家机构使用伽玛刀放射外科治疗非典型和恶性脑膜瘤的经验,并根据世界卫生组织(WHO)的最新分类进行了分层。
回顾性分析了2000年7月至2011年7月期间接受伽玛刀放射外科治疗的31例非典型脑膜瘤患者和4例恶性脑膜瘤患者。所有患者均曾接受过手术切除。总生存期是主要终点,脑内疾病复发率是次要终点。纳入了曾接受过放疗或手术切除的患者。采用Kaplan-Meier法和Cox比例风险模型来估计生存期,并确定预测复发和生存的因素。
11例患者(31.4%)出现伽玛刀治疗后复发,中位总生存期为36个月,无进展生存期为25.8个月。9例患者(25.7%)死亡。三年总生存期(OS)和无进展生存期(PFS)率分别为78.0%和65.0%。WHO二级的三年OS和PFS分别为83.4%和70.1%,而WHO三级的三年OS和PFS分别为33.3%和0%。单因素分析显示,有良性脑膜瘤病史、核异型性、高有丝分裂率、自发坏死以及WHO三级诊断的患者复发率显著更高;多因素分析显示只有WHO三级诊断具有显著性。单因素分析显示,WHO三级诊断、良性脑膜瘤病史、既往分次放疗、肿瘤体积较大以及等中心数量较多的患者总生存期受到不利影响;多因素分析显示WHO三级诊断和治疗的肿瘤体积较大具有显著性。
非典型和间变性脑膜瘤仍然是难以治疗的肿瘤。在接受放射外科治疗的侵袭性脑膜瘤患者中,多因素分析显示WHO三级诊断和治疗的肿瘤体积对复发和生存具有显著预测作用。肿瘤体积较大预示生存期较差,而核异型性、坏死和有丝分裂率增加是复发的危险因素。临床和病理预测因素可能有助于识别复发风险较高的患者。